Dr. Sankarprasad Bhuniya currently serves as Research Professor at Amrita Center for Industrial Research & Innovation and Amrita Center for Excellence in Advanced Materials and Green Technologies.
Dr. Sankarprasad Bhuniya did M. Sc. in Chemistry (1995) and Ph. D. (Polymer) from Indian Institute of Technology, Kharagpur in 2000.
He worked in Korea Basic Science Institute, Ochang, South Korea (2013-2014) prior to join in Amrita Vishwa Vidyapeetham. He did postdoctoral research in Pohang University of Science and Technology (POSTECH, 2003—2006), South Korea. He worked in the field of nucleic acid chemistry and supramolecular hydrogel. After spending short-time ( July-Dec. 2006) research at BCPS Department in Illinois institute of Technology, USA retuned to India and joined as Senior Scientist to GVK Bioscience private limited (2007-2009). Later he moved to Korea and joined as Research Professor to Korea University (2009- 2013). He has major research expertise in the field of theranostic drug delivery system for cancer therapy; biomaterials for bioimaging using fluorogenic and MRI modalities. He has published 34 research articles in peer reviewed international journal in chemistry & biomaterials with average impact factor 6.00; Scopus citation index 995 & h- index 17 and 3 patent publications.
||IIT Kharagpur, India
||IIT Kharagpur, India
||Calcutta University, WB, India
|Oct 2014 – Present
||Professor, Department of Chemical Engineering and Materials Science, Amrita Vishwa Vidyapeetham
|Feb. 2013-Sept 2014
||Division of MR Research, Korea Basic Science Institute, S. Korea
|Aug. 2009-Jan. 2013
||Department of Chemistry, Korea University, S. Korea
|Jan. 2007-Jul. 2009
||GVK Biosciences Pvt. Ltd. India
|Jul. 2006-Dec. 2006
||IIT, Chicago, USA
|Aug. 2003-Mar. 2006
||POSTECH, S. Korea
|Sept. 2001-Jul. 2003
|Aug. 2000-Jul. 2001
||Universal Agrochem. Industries, Kolkata, India
- Theranostic prodrugs: The advances in genomics, proteomics, and bioinformatics have directed to develop new type of healthcare system to reduce the drug abuse, safety and precise treatment. In search of innovative product for health care, the term, “theranostic” gained interest in clinical science. It is an appealing formulation in combination of diagnosis and therapy to improve the biodistribution and systematic administration of therapeutic in the target place. Importantly, it could be provided clear-cut solution for long time pending diseases, namely, genetic diseases and oncogenic diseases. Present needs motivated us to develop “theranostic” as future of personalized healthcare.
- Molecular Sensor (Chemo-sensors & bio-sensors): To understand the chemical transformation at the molecular level in the cellular milieus is challenging and it motivates the chemist to search new way to learn the biological system. Thus bio-inspired emerging strategy for fluorescent based bio-imaging is to sort and identify the species of interest within this complex microenvironment by exploiting differences in molecular reactivity.
- MRI Contrast Agent: Magnetic resonance imaging is widely used as clinical imaging tools which provide noninvasive three dimensional spatial images of hard and soft tissues as well. Clinically, one third cases gadolinium based contrast agents are used to enhance image contrast. Presently contrast agents are incapable to provide brighter images under higher magnetic field scanner as because of high tumbling motion, mono hydration number of gadolinium complex. Additionally, the conventional MRI contrast agents are incapable to give meaningful information on various metabolic irregularities which are being associated with various diseases etc. Thus, challenge has been focused to develop gadolinium/manganese based T1 MR Contrast agent which can provide information / interrogate on metabolic process.
Publications: 57 (published/accepted) (Citation 2210); h-index: 23)
Peer Reviewed International Journals (Under Review)
- Kim, E. J., Bhuniya, S.; Lee, H.; Kim, H. M.; Cho, J.-H.; Shin, W-S.; Kim, J. S. and Hong, K.-S., “Dual imaging probe with Gd-enhanced magnetic resonance and BODIPY near-infrared fluorescence” , Chemical Communications (Under Review); IF: 6.718
- Kumar, Rajesh, Shin, W. S.; Sunwoo, K.; Kim, W. Y.; Koo, S. Bhuniya,* S. and Kim* J. S., “Small molecule based theranostic agents: an encouraging approach for cancer therapy”, Chemical Society Reviews, (Under Review); IF: 30.425 ( review proposal accepted)
Seminars and Workshops – Invited Talks
- Bhuniya, S. “Enzyme responsive smart MRI T1 contrast agent”, the 2nd International Congress on MRI (ICMRI 2013) & The 19th Annual Scientific Meeting of KSMRM (KSMRM 2014), Seoul, South Korea. March 28-29, 2014.
Awards & Honors
- International Award: Brain Pool Fellow: National Research Foundation – Korea Republic; April 2018
- National eligibility Test (NET) for Lectureship & Junior Research Fellowship in Indian Universities and Colleges, conducted by Council of Industrial Research &Technology (CSIR), 1994
- Qualified in the Graduate Aptitude Test in Engineering (GATE) conducted by the All India Council for Technical Education, India for a fellowship, 1995; 99.51 (percentile, 10th in all India rank)
Membership in Professional Bodies
- Professor Sukumar Maiti Polymer Award Foundation– Life Member.
- The International Society of Magnetic Resonance Imaging in Medicine, Member, 2004-2015.
- “GSH activatable graphene based anti cancer theranostic tool”, Yamini Yasoda, Department of Biomedical Engineering, 2015-2016 (Dr. Nikhil Kothurkar)